Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com

Please find enclosed a Press Release

on "Dr. Reddy's Laboratories announces the launch of Sevelamer Carbonate for Oral Suspension in the U.S.

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Reddy's Laboratories announces the launch of

Carbonate for Oral Suspension in the U.S. Market

India and Princeton, NJ, USA. December 27, 2018 - Dr. Reddy's Laboratories Ltd.

(BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today

announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic

version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).

Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent twelve months ending in October

2018 according to IMS Health*.

Reddy's Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90.

is a trademark of Sanofi.

National Sales Perspective: Retail and Non-Retail MAT October 2018

Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical

company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical

Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products

and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major

therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's

operates in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For

more information, log on to: www.drreddys.com

This press release may include statements of future expectations and other forward-looking statements that are based on the management's

current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance

or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking

by reason of context, the words "may", "will", "should", "expects", "plans",

"intends", "anticipates", "believes", "estimates", "predicts", "potential",

or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may

differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance

of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity

of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive

factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions

or reorganization , including related integration issues.

company assumes no obligation to update any information contained herein.